<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343613</url>
  </required_header>
  <id_info>
    <org_study_id>16786</org_study_id>
    <secondary_id>I9L-MC-JZCA</secondary_id>
    <secondary_id>2017-002693-39</secondary_id>
    <nct_id>NCT03343613</nct_id>
  </id_info>
  <brief_title>A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the study drug LY3381916 administered
      alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody
      (LY3300054).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
    <description>Number of participants with DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3381916</measure>
    <time_frame>Predose Lead in Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: Cmax of LY3381916</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Plasma Concentration Curve (AUC) of LY3381916</measure>
    <time_frame>Predose Lead in Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: AUC of LY3381916</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3381916 Administered in Combination with LY3300054</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: Cmax of LY3381916 administered in combination with LY3300054</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of LY3381916 Administered in Combination with LY3300054</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: AUC of LY3381916 administered in combination with LY3300054</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3300054 Administered in Combination with LY3381916</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: Cmax of LY3300054 administered in combination with LY3381916</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Minimum Plasma Concentration (Cmin) of LY3300054 Administered in Combination with LY3381916</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: Cmin of LY3300054 administered in combination with LY3381916</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 12 Months)</time_frame>
    <description>ORR: Percentage of participants with a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Baseline to Date of CR or PR (Estimated up to 12 Months)</time_frame>
    <description>TTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 12 Months)</time_frame>
    <description>DCR: Percentage of participants who exhibit SD, CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated Up to 12 Months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Brain Metastasis</condition>
  <arm_group>
    <arm_group_label>LY3381916 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 + LY3300054 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally and LY3300054 administered intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 + LY3300054 Expansion (NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally and LY3300054 administered IV in NSCLC (PD-L1/PD-1 naive).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 + LY3300054 Expansion (SCCHN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally and LY3300054 administered IV in SCCHN (PD-L1/PD-1 naive).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 + LY3300054 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally and LY3300054 administered IV in PD-L1/PD-1 resistant NSCLC, SCCHN and bladder, and NSCLC with brain metastasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3381916</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3381916 Escalation</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Escalation</arm_group_label>
    <arm_group_label>LY3381916 Expansion</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion (NSCLC)</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion (SCCHN)</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3300054</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3381916 + LY3300054 Escalation</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion (NSCLC)</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion (SCCHN)</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have histological or cytological evidence of a diagnosis of cancer
             that is advanced and/or metastatic.

          -  Have adequate organ function.

          -  Have a performance status (PS) of â‰¤1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

          -  Have discontinued previous treatments for cancer.

          -  Are able to swallow capsules.

        Exclusion Criteria:

          -  Currently enrolled in a clinical study.

          -  Have a serious concomitant systemic disorder.

          -  Have a symptomatic human immunodeficiency virus infection or symptomatic
             activated/reactivated hepatitis B or C.

          -  Have a significant cardiac condition.

          -  Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IU Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-278-8845</phone>
    </contact>
    <investigator>
      <last_name>Bert O'Neil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7615</phone>
    </contact>
    <investigator>
      <last_name>SMO Sarah Cannon Research Inst.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Johanna Bendell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDO-1 Inhibitor</keyword>
  <keyword>IDO1 Inhibitor</keyword>
  <keyword>IDO Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

